ArticleJACC. Advances2026
Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis: The Prospective MoRBiDA Study.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of cardiac involvement in light-chain (AL) amyloidosis remains challenging despite its prognostic importance. [18F]-florbetaben positron emission tomography/computed-tomography (F-PET) shows promise for amyloid detection.
objectivesThe authors report results from the prospective MoRBiDA (Molecular, magnetic resonance, and echocardiographic imaging combined with biomarkers of cardiac and clonal disease to predict survival and assess response to therapy in cardiac AL amyloidosis) study integrating multimodality imaging in treatment-naive AL amyloidosis patients to evaluate F-PET diagnostic sensitivity and correlations with established markers.
methodsPatients with suspected cardiac involvement underwent baseline echocardiography, cardiac magnetic resonance (CMR), and F-PET. Cardiac involvement was defined by consensus criteria. F-PET included 50-minute dynamic cardiac acquisition (static reconstructions at ∼15 and 50-min postinjection), delayed static scan at 110 min, and myocardial tracer retention. Positive uptake was defined by visual myocardial retention exceeding blood-pool/background plus quantitative mean and maximum standardized uptake value.
resultsOf the 28 enrolled patients, 25 had cardiac involvement (3 patients without cardiac involvement had no myocardial-uptake). Early and late F-PET uptake (15-50 min) was present in all 25. Delayed uptake (110 min) was absent in 4/25 (84% sensitivity); these showed retention up to 50-min with typical CMR findings. F-PET parameters correlated moderately with N-terminal pro-B-type natriuretic peptide (standardized uptake value rho = 0.40-0.54, P < 0.05) and echocardiographic global longitudinal strain (myocardial tracer retention rho = 0.70, P < 0.001) but not with CMR-derived extracellular volume.
conclusionsEarly-to-late F-PET demonstrates excellent sensitivity for cardiac AL amyloidosis. Delayed (110-min) retention is not universal, indicating variable washout kinetics that limits its discriminatory value for amyloid typing vs late imaging or multiorgan analysis. Extracellular volume may not fully capture amyloid burden. These findings complement recent multicentric data and support further studies on optimal timing and volumetric metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.